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In cancer pharmacology (and many other areas), most dose-response curves are satisfactorily 
described by a classical Hill equation (i.e. 4 parameters logistical). Nevertheless, there are instances 
where the marked presence of more than one point of inflection, or the presence of combined 
agonist and antagonist effects, prevents straight-forward modelling of the data via a standard Hill 
equation. Here we propose a modified model and automated fitting procedure to describe dose-
response curves with multiphasic features. The resulting general model enables interpreting each 
phase of the dose-response as an independent dose-dependent process. We developed an algorithm 
which automatically generates and ranks dose-response models with varying degrees of multiphasic 
features. The algorithm was implemented in new freely available Dr Fit software (sourceforge.net/
projects/drfit/). We show how our approach is successful in describing dose-response curves with 
multiphasic features. Additionally, we analysed a large cancer cell viability screen involving 11650 
dose-response curves. Based on our algorithm, we found that 28% of cases were better described 
by a multiphasic model than by the Hill model. We thus provide a robust approach to fit dose-
response curves with various degrees of complexity, which, together with the provided software 
implementation, should enable a wide audience to easily process their own data.
Measuring drug effects on biological systems is part of many scientists’ routine1,2. Observed effects span 
from the inhibition or agonism of proteins and other molecules3,4 to effects measured at the cell5, tissue6 
or whole organism levels7,8. In cancer research, cell proliferation and viability are often assessed in a 
panel of cell lines specific to a given type of cancer9. Typically, the biologist or pharmacologist compares 
populations of treated vs. untreated cells at various drug concentrations. The data is summarized via 
a dose response curve and then fitted using an in-house program or commercial software. The fitted 
curve gives a mathematical description of measured effects and enables interpolating or extrapolating 
missing information. When various cell lines or drugs are also investigated, the resulting models facilitate 
comparing dose-responses by summarizing them via a few parameters10 (e.g the relative 50% effective 
concentration EC50).
The fitting procedure that follows data acquisition can be challenging from several point of views. 
First of all, for most experimentalists who are not familiar with modelling, this procedure will require the 
availability of friendly software to fit the data. Moreover, most available programs will attempt to fit the 
data to a standard Hill model (also called 4 parameters logistic11). The Hill model has been used exten-
sively in the past. It can describe chemical reactions in mechanistic terms12 and enables excellent model-
ling of most cases. However, the Hill model is based on a unique point of inflection and cannot faithfully 
describe cases where agonist (stimulatory or hormetic) effects are also observed13,14. Moreover, even in 
the absence of agonist effects, cases where there is more than one point of inflection in the inhibitory 
phase cannot be handled15. This can result in poorly fitted curves which can mislead data interpretation, 
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comparison to other cases, and extrapolation if such fits are accepted. Recently, Haibe-Kains et al.16 
identified the choice of an estimator for summarising drug dose-response curves as one of the reasons 
for lack of correlation of drug sensitivity in large pharmacogenomics screens17,18. At the same time, the 
importance and implications of multiphasic dose-responses have been highlighted in various contexts19,20 
including cancer therapeutics21,22.
Extensions of the Hill model for asymmetrical curves have been developed, but these do not accommo-
date several points of inflection23–26. Alternatives have been suggested to handle biphasic dose-response 
curves27,28. These were tailored to the specific case of an initial stimulatory effect and are not necessarily 
equipped with a common structure and straightforward interpretation of the resulting model. There have 
also been a number of efforts in improving dose-response fitting29,30 and several free software products 
are available to fit dose-response curves31–34. These efforts often focused on the standard Hill model 
and did not provide a free tool which can be used to generate multiphasic dose-response models in a 
user-friendly manner as per well-known commercial packages35–37. Note that there also exists general 
free language and environment such as R38 which easily enable cubic splines fitting (splines are curves 
generates by connecting polynomials). Nevertheless, splines fitting is not optimal due to the lack of 
model structure which affects the goodness of fit and prevents interpretation in mechanistic terms.
Here we present a general model which enables excellent fitting of dose-response curves with mul-
tiphasic features. From a theoretical point of view, this new model combines dependent, cooperative 
effects as described by a Hill model, with independent effects as suggested by the Bliss approach for 
combination studies39. We show that non-regular cases encountered in cancer pharmacology can be 
satisfactorily handled by this approach which combines these two classical pharmacological models. We 
have developed an algorithm which enables automated fitting of dose-response curves and have imple-
mented it in freely available software (Dr-fit as per Dose-response Fitting). This approach was successful 
in modelling dose-responses which could not be described by a standard Hill equation. We then analysed 
a large screen involving 11650 dose-response curves and found that a substantial proportion of cases 
were better described by this approach.
Results
From Hill to multiphasic models. The Hill model is based on the following equation which describes 
the effect E obtained at a given concentration C:
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where EC50 is the relative 50% effective concentration, H is the hill exponent, E∞ is the maximum effect 
and E0 is the effect in the absence of drug. This equation can also be manipulated and written under 
alternative forms or via different definitions of its parameters. If the dose response is built by considering 
a measure of the system being studied (e.g. amount of cells or of proteins) in treated conditions over this 
same measure in untreated conditions, then the baseline value E0 is fixed to unity (the dose-response 
can also be expressed in terms of percentage as it is done here). Figure 1a shows the typical sigmoidal 
curve that is obtained with the Hill model. The figure also shows that varying the EC50 shifts the curve in 
log-space while varying the E∞ changes the effect level obtained at high concentrations (Fig. 1b). Finally, 
the hill exponent H can be used to account for various degrees of steepness (Fig.  1c). This model can 
therefore be used to fit typical dose-response curves encountered in pharmacological studies (Fig. 1d).
In a significant number of cases, dose-response curves show stimulatory effects (notably at low con-
centration; Fig. 2a), or two point of inflections (Fig. 2b), or even a combination of these features (Fig. 2c). 
In these cases, it is obvious that attempting to fit the data to a Hill model cannot result in a satisfactory 
description of the data (red lines in Fig. 2a–c). Here we propose a modelling approach that is based on 
breaking down each one of the observed phases into independent, separate processes. Then each of these 
distinct processes is considered as the observed effect of closely related sub-processes. The mathematical 
formulation of this approach is as follows.
We first consider each phase separately and model it using a standard Hill model. For each phase i 
we write:
( , , ) = +
−
+ ( / ) ( )
∞
∞E C E EC H
E
EC C
; 1
1
1 2i i i i
i
i
Hi50
50
Then we consider each one of these phases as being part of successive reactions which independently 
converge toward the same phenotype, thus resulting in the total effect E:
∏( ) = ( ) ( )E C E C 3i
n
i
where E(C) is the observed dose-response curve, and Ei(C) is the dose response curve corresponding to 
the underlying ith independent process. Note the well-known similarity between this formulation and 
the probability of independent events. This leads to the following model when considering all phases:
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Note that this formulation is only correct when the response in the absence of drug is unity. Alternative 
formats can nevertheless be obtained by scaling this equation appropriately. Using this model with n = 2 
Figure 1. Standard Hill model. (a) The Hill model enables generating sigmoidal dose-response curves. 
It can be shifted in concentration space by varying its EC50 parameter. (b) The E∞ parameter (also called 
Emax) can be used to modulate effects at high concentration. (c) The Hill coefficient modulates the slope of 
the curve. (d) The flexibility of this model captures dose-response data in most cases (here an example of 
Gemcitabine in the Panc-1 cell line is shown).
Figure 2. Non-monophasic cases. (a) In a number of instances, observed dose-responses are not 
monophasic. In this example (Gemcitabine in the K8484 cell line), an initial stimulatory effect can be 
observed. (b) There are also instances where two points of inflection are observed in a dose-response with 
purely inhibitory features (here an example of PF477736 in the Skov3 cell-line is shown). (c) In some cases, 
both the presence of an initial stimulatory effect and two phases in the inhibitory range can be observed 
(here an example of CHK1i in the Panc-1 cell-line is shown). In all these cases, the dose-response cannot be 
captured with the optimization of a standard Hill model (red lines).
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two phases of inhibition (Fig. 3a) or one stimulatory and one inhibitory phase (Fig. 3b) can be described. 
Using n = 3, a multiphasic dose response with one stimulatory and two inhibitory phases can be described 
(Fig. 3c). There is no theoretical limit and for instance using n = 5, we can also describe more complex 
dose-response curves such as one that involves two stimulatory and three inhibitory phases (Fig. 3d).
It is important to realize that the higher the number of process incorporated (i.e. the greater is n), 
the more it is difficult to experimentally discern the presence of each process due to inherent biological 
variation and experimental error. Also, the inclusion of each additional phase requires 3 parameters, so 
for n = 3 phases, 9 parameters are required. Therefore we compared the classical mono-phasic case (Hill 
equation) with three configurations only. These were cases where two stimulatory (n = 2), or one stimu-
latory and one inhibitory (n = 2), or one stimulatory and two inhibitory phases (n = 3) were present. In 
our experience, these configurations enable to describe most cases encountered in cancer pharmacology.
Automated curve fitting. We developed an optimization process to automatically generate and pro-
vide models with either one phase of inhibition, two phases of inhibition, one stimulatory and one 
inhibitory phase, or one stimulatory and two inhibitory phases. Our approach was based on an optimi-
zation algorithm and a ranking test40 which were both incorporated in the Dr-Fit software (Fig. 4; http://
sourceforge.net/projects/drfit/). Details of the overall method, including the formulation of the optimized 
objective function and how to use the software, can be found in the methods section.
Our approach was used to model the three examples of multiphasic dose-response curves shown in 
Fig. 2 and resulted in excellent descriptions of the data (Fig. 5). Each case was classified as a mono-phasic 
or multiphasic dose-response based on the Bayesian Information Criterion (BIC). The BIC criterion 
enables robust model ranking and selection and is based on a Bayesian approach40. The BIC criterion 
was chosen here over other classical ranking methods because it penalizes over-fitting more than other 
well-known ranking criteria41–43. Thus a conservative approach is used here where simpler models are 
favoured versus more complex multi-phasic ones.
Using this approach, the first case was recognized as a 2 processes model involving a stimulatory 
and an inhibitory phase (Fig. 5a). The second case was recognized as a 2 processes model involving two 
inhibitory phases (Fig. 5b). The third case was recognized as a 3 processes model involving a stimulatory 
and two inhibitory phases (Fig. 5c). We then wanted to assess what proportion of cases might be better 
described by a multiphasic dose-response curve rather than a standard Hill equation.
As an example, we analysed 11650 dose-response experimental cases available from the Cancer Cell 
Line Encyclopedia (CCLE)17,44. This data-set was generated using High-Throughput Screening (HTS) 
technology and its analysis presents several challenges. First, the very large amount of data precludes 
Figure 3. New general multiphasic model. Our model enables description of a variety of dose-response 
cases where various phases are present. Simulated examples are shown for hypothetical cases with (a) two 
inhibitory phases, (b) one stimulatory and one inhibitory phase, (c) a combination of a stimulatory and two 
inhibitory phases. (d) A complex example involving two stimulatory and three inhibitory phases.
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visual inspection of each case. Second, the noisy nature of HTS generated data complicates model identi-
fication. Our approach was successful in analysing this data-set and showed that (Fig. 6a), based on our 
BIC ranking test, overall 72% of cases could be explained using a monophasic standard Hill equation 
(e.g. Fig.  6b). Thus, a substantial proportion of dose-responses were found to be better described by a 
multiphasic approach (28%). Most of these were appropriately described by a biphasic model with an 
Figure 4. Dr-Fit software. Dr-Fit (Dose-response fitting) is freely available software which implements our 
model and algorithm. It enables fitting dose-response curves with complex multiphasic features. (a) User-
friendly interface enables data access, option selection, running the algorithm and saving the results. (b) 
Experimental data is saved in .xls file (in this example one replicate and three concentration points). (c) 
Several replicates and various concentration points can be used (here the example has been expanded to 
four replicates and seven concentration points). (d) The uploaded data is displayed in the top-right panel.  
(e) Following the model-building process, the resulting curve is also displayed in the same panel. (f) 
The figure legend and limits can be modified through the centre-right panel. (g) The plot can then be 
automatically saved in high quality .png figures (resulting figure is shown) or accessed and saved in 
alternative formats. (h) Model’s parameters can also be saved in the project’s folder. (i) Effects can be 
interpolated or extrapolated via the bottom left panel. (j) Additionally, effective concentrations can be 
computed for any desired effect (e.g. EC50). Here the EC90 which is the effective concentration that gives a 
90% effect has been calculated.
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Figure 5. Modelling non-monophasic cases. Our new model and method enable to also describe 
experimental dose-responses which are not monophasic. (a) Our first (initial stimulatory effect), (b) second 
(two inhibitory phases) (c) and third example (initial stimulatory effect and two inhibitory phases) are well 
described by the resulting model in each case (red line).
Figure 6. Large scale analysis of dose-response types. We analysed 11650 dose-response experimental 
cases available from the Cancer Cell Line Encyclopedia (CCLE). (a) Histogram showing the distributions 
of models which better described each case. (b) An example of monophasic case. (c) An example where an 
initial stimulatory phase is present (also termed hormesis). (d) An example where two inhibitory phases are 
present. (e) An example where both an initial stimulatory phase and two inhibitory phases are present.
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initial stimulatory effect (16%, e.g. Fig. 6c). A substantial number (8%) was appropriately described with 
two point of inflection (e.g. Fig. 6d) and only 4% required a triphasic model (e.g. Fig. 6e).
Discussion
Dose-response curves are routinely generated in the laboratory environment to assess the effect of drugs 
and other agents on molecular, cellular and other models. In most cases, a single inflection dose-response 
is observed which can be modelled using a classical Hill model. Nevertheless, there are instances where 
dose-responses show an initial stimulatory effect (also termed hormesis20) or is fully inhibitory but with 
two point of inflections (bi-phasic). In a number of instances, a combination of these features can be 
observed. It is often desirable to model the observed dose-response in order to obtain a mathematical 
description which can also be used to interpolate, extrapolate or derive metrics such as EC50 or maxi-
mum effects.
The challenge in identifying and modelling multi-phasic dose-response curves can be attributed to 
the increased complexity and decreased interpretability of potential approaches to model multiphasic 
dose-responses. Increased complexity is often associated to poor fitting or difficulty in generating appro-
priate fitting, particularly for experimentalists who are not necessarily familiar with these procedures. 
We have therefore developed a general model which we encapsulated in a fitting-ranking procedure and 
software, producing a robust, user-friendly tool.
Most advances in modelling dose-response data have focused on hormetic effects and have been made 
in the fields of toxicology and environmental science28,45–49. Our approach is based on simply combining 
the classical Hill and Bliss models and enables describing dose-response data with complex multipha-
sic features. Thus we explain observable inflections as the result of perturbing underlying independent 
processes (Fig. 7). Each Hill model term in our formulation can be interpreted as the effect of the drug 
interacting with a series of converging, cooperative processes12 (e.g. interaction with a specific biological 
pathway). The product of these Hill model terms can then be interpreted in terms of perturbed processes 
(e.g. pathways) which are independent50. Therefore our approach enables describing dose-response data 
in a robust manner and it also offers interpretation in broad mechanistic terms.
It should be noted that dose-response curves, including those with two or more inflections, can in 
theory be fitted using splines51,52 or other polynomials-based approaches53,54. The question therefore 
arises to why an alternative approach such as ours would be useful. We believe that the answer to this 
question is rooted in the same reasons which make the use of the classical Hill model popular for 
traditional monophasic dose-response curves. The first reason is that the number of parameters used 
with splines fitting increases linearly with the number of knots (the points where the polynomial pieces 
connect). This adversely affects the goodness of fit as measured via a maximum likelihood approach. The 
second reason is that when using splines, the resulting dose-response model is not indicative of potential 
underlying mechanisms. This is not the case in our approach where the resulting model structure indi-
cates if there is a stimulatory effect or/and a second inhibitory phase (which could indicate interference 
with distinct processes). Also, the parameters do not correspond to specific features of the curve (steep-
ness, half inhibitory concentration, maximum effect). In respect of all these points, our model is in line 
with the classical Hill model and can be viewed as an extension of it in the case of multiphasic cases.
We have also developed an algorithm which enables determination of how many processes can be 
observed (in order to tailor the model at the right level) based on statistical consideration. The resulting 
procedure has been integrated in our newly developed user-friendly Dr-Fit software. We also proceeded 
to analyse a large data-set and showed that, based on models ranking, a substantial number of cases 
Figure 7. Mechanistic interpretation of our generalized Hill model. A specific phenotype (for instance 
cell proliferation) is often the result of several converging pathways. Some pathways result in stimulating a 
phenotype while others might inhibit it. (a) A drug may inhibit a specific node of a stimulatory pathway, 
resulting in a monophasic dose-response as per the classical Hill model. (b) In some cases a drug may 
affect several nodes, possibly in different stimulatory pathways and with different potency. If the difference 
in potency is great enough, this might lead to a clearly observable bi-phasic dose-response. (c) If the drug 
inhibits an inhibitory pathway at lower concentration, a stimulatory phase can also be observed.
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do not fit the Hill model and might require multiphasic models (28%). It should be noted that sev-
eral authors already highlighted the importance and implications of multiphasic dose-response such as 
hormetic effects19,20. More recently, the relevance of complex dose-response mechanisms has also been 
highlighted in the context of cancer therapeutics21,22. Our finding that a substantial proportion of a large 
data-set is better described by a multiphasic model might suggest that these effects are not exceptionally 
rare.
From a practical point of view, this approach enables classifying observed dose-response in a number 
of ways. It enables the user to distinguish between mono- vs. multi-phasic dose-response. It also ena-
bles the user to distinguish between various types of multi-phasic features (e.g. stimulatory + inhibitory 
phases vs. stimulatory + 2 inhibitory phases). Moreover, more quantitative comparisons across agents 
or systems can be performed using parameters such as the EC50 for each one of the identified phases. 
Parameters also provide mechanistic insight, for instance in terms of understanding at what concentra-
tion level a specific process is engaged (e.g. first inhibitory vs. second inhibitory phase).
Interpolation and extrapolation exercises are improved using this approach. This can have impact in 
a number of instances, such as for instance in the case of assessing drug combinations55. It should also 
be noted that other important metrics such as the area under the curve (AUC) can be derived from 
the dose-response model56. For instance, the AUC together with the IC50 were considered to compare 
the results of two large-scale pharmacogenomics studies16. The calculation of such metrics should also 
benefit from our new approach.
The implementation of our general model and method in Dr-Fit software should enable robust pro-
cessing of both standard dose-response curves and multiphasic ones. We expect Dr-Fit to be a tool useful 
for many experimentalists and analysts interested in the study of agent effects on biological systems.
Material and Methods
Modelling. The model introduced in the Results section was implemented using Matlab. A three 
processes model was implemented using the following equation:
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Dr-Fit software reads the dose-response data and builds the model. The algorithm implemented in 
Dr-Fit first attempts to fit the data to a one process model (i.e. a standard Hill equation). This is followed 
by an attempt to fit the data to a two inhibitory processes model. Then Dr-fit attempts to fit the data to 
a two processes model which includes a stimulatory process. Finally, the software attempts to fit the data 
to a three processes model, two of them being inhibitory (antagonist) and one stimulatory (agonist). 
Three optimization algorithms were implemented to find the model parameters: the simplex constrained, 
the Trust-region-reflective and the standard simplex. The Simplex constrained is the same algorithm as 
per the Simplex but constrains the parameters of the stimulatory and inhibitory processes such that no 
overlap in concentration space occurs (well separated processes). For all optimization algorithms, the 
following function F is minimized:
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where cj corresponds to the jth concentration (p concentrations), Eexp i (cj) corresponds to the measured 
effect for concentration level cj and replicate i (n replicates), and σj is the standard deviation obtained for 
all the measures at concentration cj. For models with only two processes EC50 3, H3 and E∞3 were fixed 
to 1. For the model with only one process (i.e. a Hill model), EC50 2, H2 and E∞2 were also fixed to 1.
For normally distributed observational noise, minimizing our function F corresponds to a maximum 
likelihood estimate of the parameters. Thus, when more than one replicate is available, goodness of fit 
(GOF) can be tested for and is also provided by the software. The resulting four models are then ranked 
based on the Bayesian Information Criterion (BIC) and the model with the lowest BIC score is proposed 
by the software as the best model40. The BIC is our favourite ranking score because it favours simpler 
models, thus avoiding overparmetrization41–43 (the Akaike Information Criterion57 (AIC) score is also 
provided by the software if needed). In some instances, the absence of an appropriate number of rep-
licates prevents satisfactory assessment of the standard deviation. In this case the software also enables 
weighting the sum of squares in the function F by unity rather than the standard deviation.
It is also important to note that, if we assume for instance that the dose-response data is normalized 
to control conditions (no drug), then measured effects vary from 1 at low concentration to a value often 
close to 0 at high concentration. In practice, it is possible that fluctuations lead to a poor estimation of 
control conditions (i.e. not enough replicates, spatial effects in plated experiments etc.) such that the 
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baseline may appear greater or lower than 1. Thus, the option is given to also scale the model in order 
to capture a different baseline and minimize these effects.
Software main features. Dr-Fit software was developed to enable end-users to easily model their 
dose-response data without requiring any coding or scripting. The software can be downloaded from 
sourceforge.net/projects/drfit and it is easily installed on windows-64 machines. Dr-Fit is accessible 
through an user-friendly interface (Fig. 4a). Experimental data is simply tabulated in a .xls file (Fig. 4b) 
and there are no limits in terms of concentration points and number of replicates (Fig. 4c; each replicate 
is simply added next to the previous one). The data for the software should be ordered as follows: con-
centrations, effects for replicate 1, effects for replicate 2 etc, then concentration unit and then title. The 
data can be ordered either in column or rows and several formats for the dose-response can be selected 
(Effects varying from 1 to 0 or 100 to 0 or 0 to 1 etc). A template and several examples are provided 
online.
Once the data is loaded, it is displayed in the right panel of the software (Fig.  4d). The user can 
then proceed to automatically produce a model which will be also displayed in the right panel. Upon 
pressing the “Fit curve” button, Dr-Fit proceeds to automatically fit the data (Fig. 4e). The plots can be 
further modified (Fig. 4f) and saved as high quality figures (Fig. 4g). The models’ characteristics (param-
eters, scaling, χ 2, GOF, AIC and BIC) can also be saved in a .xls file in the project’s folder (Fig.  4h). 
Additionally, effects can be interpolated or extrapolated at various concentrations (Fig. 4i) and effective 
concentration at 50% (i.e. EC50 of the overall) or at any other level (e.g. EC90) can be calculated via 
Dr-Fit interface (Fig. 4j). Several dose-response curves can be displayed in the right panel (with same or 
different colour) and the whole figure saved with high resolution.
Cells and reagents. The KPC K8484 cancer cell line was established from a KPC PDAC tumour58. 
PANC-1 cells were obtained from the European Collection of Cell Cultures (ECACC; Health Protection 
Agency, Salisbury, UK) and were verified by STR genotyping and tested negative for mycoplasma. Cells 
were grown in DMEM medium (Life Technologies) supplemented with 5% fetal calf serum at 37 °C and 
5% CO2. SKOV3 cells were obtained from ATCC and tested negative for mycoplasma. They were grown 
in RPMI medium (Life Technologies) supplemented with 5% fetal calf serum at 37 °C and 5% CO2. 
Gemcitabine was obtained from Tocris Bioscience (Bristol, UK).
Gemcitabine was dissolved in dimethylsulphoxide (DMSO) and then diluted in culture medium to 
a final concentration of 0.2% DMSO. PF477736 was obtained from SynKinase (Parkville, Austrailia), 
dissolved in DMSO at 10 mM, and serially diluted to the appropriate concentration.
Cytotoxicity assay. For K8484 and PANC-1, drug cytotoxicity in vitro was assessed by the means of 
Sulforhodamine B colorimetric (SRB) assay. Cells were plated with a range of concentrations. After 72 h 
of incubation at 37 °C, they were fixed (3% trichloroacetic acid in water (w/v), 90 minutes, 4 °C), washed 
in water and stained with a 0.057% SRB (Sigma) solution in acetic acid (w/v) for 30 minutes. The plates 
were washed (1% acetic acid (v/v), 4 times), and the protein-bound dye was dissolved in a 10 mM Tris 
base solution (pH 10.5). Fluorescence was measured using Tecan Infinite M200 plate-reader (excitation 
488 nm, emission 585 nm). Percentage inhibition compared to solvent control-treated cells was calculated 
for each drug concentration.
For SKOV3, drug toxicity was assessed by cell titer glo. Approximately 500 cells per well in 5 uL 
was dispensed using a Multidrop Combi dispenser (Thermo Fisher Scientific) into 1,536 solid-bottom 
white Greiner Bio-one tissue culture-treated plates (catalog #789173-F). 23 nL of ). PF477736 was trans-
ferred to the assay plate using a Kalypsis pintool. Plates were covered with stainless steel cell culture lids 
and incubated at standard conditions for 48 hours. To assess viability, 3 uL of CellTiter Glo luminescent 
cell viability assay reagent (Promega) was added using a Bioraptor Flying Reagent Dispenser (Aurora 
Discovery-BD). The plates were incubated for 15 minutes at room temperature and measured using a 
10-s exposure on a ViewLux (Perkin-Elmer).
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